Last updated 9 days ago

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

3500 patients around the world
Available in Colombia, Brazil, United States, Puerto Rico, Chile
Merck Sharp & Dohme Colombia SAS
12Research sites
3500Patients around the world
This study is for people with
Solid tumors
Advanced tumors
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Centro de Investigaciones Clínicas - Clínica Viedma - Río Negro
Centro de Investigaciones Clínicas - Clínica Viedma - Río Negro
Recruiting
25 de mayo 174, Viedma, Río Negro
Hospital Privado de Córdoba
Recruiting
Naciones Unidas 346, Córdoba
Instituto de Oncología de Rosario - IOR
Recruiting
Córdoba 2457, Rosario, Santa Fe
Sanatorio Parque - Rosario
Recruiting
Boulevard Oroño 860, Rosario, Santa Fe
Centro Médico San Roque S.R.L. - Tucumán
Recruiting
Balcarce 579, Tucumán
Hospital Alemán
Recruiting
Av. Pueyrredón 1640, CABA, Buenos Aires
Instituto Oncológico FALP (Fundación Arturo Lopez Perez)
Recruiting
José Manuel Infante 805, Providencia, Región Metropolitana, Santiago
Oaxaca Site Management Organization S.C.
Recruiting
Humboldt 302, ruta Independencia, Colonia Centro, Oaxaca de Juárez, Oaxaca. México. CP 68000
Oncare Cancer Center Viaducto CdMx
Recruiting
Viad. Río Becerra 27, Nápoles, Benito Juárez, 03810 Ciudad de México
Medical Care & Research SA de CV
Recruiting
Calle 32 217 por Calle 11 y 13, Colonia Garcia Gineres, CP 97070 - Yucatán, Mérida
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy